Exciting Subcutaneous Formulation Approval In Mm

Exciting Subcutaneous Formulation Approval in MM

Targeted Oncology

What does the approval of Darzalex Faspro™ mean for myeloma patients?

International Myeloma Foundation

Practical Management of IV Daratumumab in MM

Targeted Oncology

Dr Sonneveld on the FDA Approval of Subcutaneous Daratumumab Plus VRd in Myeloma

Subcutaneous daratumumab: an update on the latest MM clinical trials

VJHemOnc – Video Journal of Hematology & HemOnc

Columba study update: subcutaneous daratumumab in R/R MM

VJHemOnc – Video Journal of Hematology & HemOnc

Novel drug delivery method to prevent daratumumab infusion-related reactions in MM

VJHemOnc – Video Journal of Hematology & HemOnc

Subcutaneous Pen Formulation FDA Approval

Results from Phase I study of alnuctamab administered intravenously & subcutaneously in R/R myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Martin on Subcutaneous Administration of Daratumumab in Multiple Myeloma

Daratumumab in myeloma update: expanding indications

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Hurvitz on FDA Approval of Subcutaneous Trastuzumab Formulation in HER2+ Breast Cancer

Dr. Martin on FDA Approval of Denosumab in Multiple Myeloma

Subcutaneous Daratumumab — Dr. Jonathan Kaufman | MCRT Webcast July 11

HealthTree Foundation for Multiple Myeloma

Dr. Harrison on Subcutaneous Daratumumab and Isatuximab in Myeloma

Subcutaneous daratumumab: combining efficacy, safety & convenience

VJHemOnc – Video Journal of Hematology & HemOnc

Understanding Darzalex Faspro

International Myeloma Foundation

Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with MM

Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers

Mezagitamab: an anti-CD38 antibody for R/R MM

VJHemOnc – Video Journal of Hematology & HemOnc